Abstract:Numerous approaches have been described to obtain variable fragments of antibodies (Fv or scFv) that are sufficiently stable for their applications. Here, we combined several knowledge-based methods to increase the stability of pre-existing scFvs by design. Firstly, the consensus sequence approach was used in a non-stringent way to predict a large basic set of potentially stabilizing mutations. These mutations were then prioritized by other methods of design, mainly the formation of additional hydrogen bonds, an increase in the hydrophilicity of solvent exposed residues, and previously described mutations in other antibodies. We validated this combined method with antibody mAbD1.3, directed against lysozyme. Fourteen potentially stabilizing mutations were designed and introduced into scFvD1.3 by site-directed mutagenesis, either individually or in combinations. We characterized the effects of the mutations on the thermodynamic stability of scFvD1.3 by experiments of unfolding with urea, monitored by spectrofluorometry, and tested the additivity of their effects by double-mutant cycles. We also quantified the individual contributions of the resistance to denaturation ([urea](1/2)) and cooperativity of unfolding (m) to the variations of stability and the energy of coupling between mutations by a novel approach. Most mutations (75%) were stabilizing and none was destabilizing. The progressive recombination of the mutations into the same molecule of scFvD1.3 showed that their effects were mostly additive or synergistic, provided a large overall increase in protein stability (9.1 kcal/mol), and resulted in a highly stable scFvD1.3 derivative. The mechanisms of the mutations and of their combinations involved variations in the resistance to denaturation, cooperativity of unfolding, and likely residual structures of the denatured state, which was constrained by two disulfide bonds. This combined method should be applicable to any recombinant antibody fragment, through a single step of mutagenesis.

Site-directed Mutations of Anti-Amantadine Scfv Antibody by Molecular Dynamics Simulation: Prediction and Validation

A Novel Variable Antibody Fragment Dimerized by the Dhlx Peptide with Enhanced Affinity Against Amantadine Compared to Its Corresponding Scfv Antibody

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity

Covalent and Oriented Immobilization of Scfv Antibody Fragments Via an Engineered Glycan Moiety

Construction of a Single Chain Variable Fragment Antibody Against Sulfonamides and Its Interaction with Sulfathiazole

[A Novel System for Discovering High-affinity Antibody Mutants That Enables Immunoassays with Higher Sensitivities -Development and Application of Clonal Array Profiling (CAP)]

Characterization of Variable Region Genes and Discovery of Key Recognition Sites in the Complementarity Determining Regions of the Anti-Thiacloprid Monoclonal Antibody

Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches

Molecular Docking And Molecular Dynamics (Md) Simulation Of Human Anti-Complement Factor H (Cfh) Antibody Ab42 And Cfh Polypeptide

Homology modeling of a fumonisin B1 specific scFv antibody and simulation study of molecular docking between the scFv antibody and its antigen

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Triple Mutated Antibody Scfv2f3 with High GPx Activity: Insights from MD, Docking, MDFE, and MM-PBSA Simulation

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies.

Production of anti-amoxicillin ScFv antibody and simulation studying its molecular recognition mechanism for penicillins.

Computational Analysis for the Rational Design of Anti-Amyloid Beta (ABeta) Antibodies

Engineering Peptide Linkers for scFv Immunosensors

AB-Amy: machine learning aided Amyloidogenic risk prediction of therapeutic antibody light chains

Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain

Engineering affinity of humanized ScFv targeting CD147 antibody: A combined approach of mCSM-AB2 and molecular dynamics simulations

Improving the Stability of an Antibody Variable Fragment by a Combination of Knowledge-based Approaches: Validation and Mechanisms

Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers.